Merck’s KEYNOTE-A18 Trial

Merck’s KEYNOTE-A18 Trial Shows Breakthrough in Cervical Cancer Treatment

KEYNOTE-A18 Trial: Primary Endpoint – Progression-Free Survival in High-Risk Cervical Cancer

SG Tylor

Source – Merck Merck has announced a groundbreaking development in its Phase III KEYNOTE-A18 trial, also referred to as ENGOT-cx11/GOG-3047. ...